Search

Your search keyword '"Murray, Elaine"' showing total 227 results

Search Constraints

Start Over You searched for: Author "Murray, Elaine" Remove constraint Author: "Murray, Elaine"
227 results on '"Murray, Elaine"'

Search Results

5. Complete genome of Escherichia colisequence type 73 with acquired blaTEM-1and high genotypic virulence load identified in human saliva

6. Precision medicine to manage chronic immune-related conditions

7. Contributors

8. Potential Plasma Proteins (LGALS9, LAMP3, PRSS8 and AGRN) as Predictors of Hospitalisation Risk in COVID-19 Patients.

9. Genomic, Proteomic and Phenotypic Biomarkers of COVID-19 Severity: Protocol for a Retrospective Observational Study (Preprint)

10. Genomic, Proteomic, and Phenotypic Biomarkers of COVID-19 Severity: Protocol for a Retrospective Observational Study

18. Genomic, Proteomic, and Phenotypic Biomarkers of COVID-19 Severity: Protocol for a Retrospective Observational Study (Preprint)

19. Inflammatory and immune response signatures associated with COVID-19 severity

21. College Student Mental Health and Wellbeing Prior to and during the COVID-19 Pandemic

22. Supplementary Table S2 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma

23. Figure S3 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma

24. Supplemental Figure 3 from Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors

25. Supplemental Figure 2 from Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors

26. Supplementary Figure 2 from A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors

27. Supplemental Figure 1 from Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors

28. Supplementary Figure 1 from A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors

29. Supplementary Data from A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors

30. Variations in psychological disorders, suicidality, and help-seeking behaviour among college students from different academic disciplines

32. Variations in psychological disorders, suicidality, and help-seeking behaviour among college students from different academic disciplines

36. Immuno-informatics analysis predicts B and T cell consensus epitopes for designing peptide vaccine against SARS-CoV-2 with 99.82% global population coverage

37. Lifetime and 12-month treatment for mental disorders and suicidal thoughts and behaviors among first year college students

41. Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma

42. ALLO-647 for Lymphodepletion in the Allogeneic CAR T Setting: Safety Experience with ALLO-501/501A in Patients (Pts) with Relapsed/Refractory (r/r) Large B-Cell and Follicular Lymphomas

45. Regional planning for the siting of local evaporation basins for the disposal of saline irrigation drainage: development and testing of a GIS-based suitability approach

46. A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors

48. A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors

Catalog

Books, media, physical & digital resources